Tippi MacKenzie, MD
Wednesday, May 20, 2026, 5:00-6:00 pm (San Francisco) Check your time zone.
This session:
In utero hematopoietic cell transplantation (IUHCT) has the potential to treat patients who have hemoglobinopathies by harnessing the unique period of fetal tolerance to maternal cells, thereby enabling semi-allogeneic transplantation without conditioning or immunosuppression. In this session, Dr. Tippi MacKenzie will present the results of a phase 1 clinical trial of IUHCT in fetuses with alpha thalassemia major, including safety, feasibility, and limitations of IUHCT for ATM. She will discuss new research to develop definitive therapies to address the unmet medical need of patients diagnosed with ATM.
The International Alpha Thalassemia Consortium brings together an interdisciplinary group of clinicians and scientists from around the world to focus expertise in hematology, maternal-fetal medicine, genetics, fetal therapy, and neonatology on alpha thalassemia major (ATM).
We gather to share advances, challenges, and best practices regarding clinical care for prenatal, pediatric, and adult patients diagnosed with ATM. Each session lasts one hour, including a 30-minute presentation, followed by moderated discussion.
